Two Onc Docs

This week’s episode will be focusing on exciting data to come at the ASCO Annual Meeting 2025 starting with the plenary sessions, then a special focus on the GU abstracts, including prostate CA, renal cell carcinoma, bladder CA, and a quick shout-out for some of the medical education sessions.

This week’s episode will be focusing on hepatocellular carcinoma (HCC). We will go over important details on assessing liver function, staging of HCC and loco-regional as well as systemic treatment options for HCC.

Jeff Auletta, a pioneer in stem cell transplantation and infectious diseases, shares insights from his role at the National Marrow Donor Program. He explores the intricacies of conditioning regimens, including myeloblative and non-myeloablative methods. The conversation delves into the complexities of graft-versus-host disease, highlighting treatment strategies and challenges. Auletta also emphasizes the importance of managing transfusion complications and shares his emotional connections with pediatric patients, underscoring the vital role of stem cell research.

Joining the discussion is Dr. Jeff Auletta, a leading voice in blood and marrow transplantation. He shares insights on hematopoietic stem cell transplants, clarifying the various types and the donor matching process. The conversation dives into the risks and benefits of autologous versus allogeneic transplants, highlighting critical disparities in donor availability across ethnic groups. Dr. Auletta also emphasizes the need for systemic changes to address socio-economic barriers and ensure equitable access to transplant services for all communities.

This week’s episode is part 2 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of non-seminoma last year, released 4/22/2024, but today, we will be repeating a quick overview of the staging and management for initial treatment of non-seminoma as well as refractory disease.

This week’s episode is part 1 of testicular cancer 2025 updates. We had the honor of interviewing Dr. Larry Einhorn a true legend when it comes to the management of testicular CA last year, released in April 2024, but today, we will be repeating a quick overview of risk factors and staging for testicular cancer, as well as the management of seminoma.

Delve into the complexities of Chronic Lymphocytic Leukemia with updates on personalized treatment strategies and the latest therapies like CAR-T and non-covalent BTK inhibitors. Unpack the diagnostic criteria, staging systems, and essential prognostic factors, including immunoglobulin mutations. Discover the balance between treatment and observation for improved outcomes, while also addressing treatment toxicities and cardiovascular risks. Gain insights into managing initial and refractory disease, ensuring effective patient care.

Dr. Charles Ryan, a leading GU oncologist from MSK in NYC, returns to share vital updates on metastatic prostate cancer. He discusses the differences between castrate-sensitive and castrate-resistant prostate cancer, crucial for treatment strategies. Advancements like PARP inhibitors and immunotherapy take center stage, alongside the necessity for genomic testing. Ryan emphasizes learning from clinical trials, whether outcomes are positive or negative. He also inspires future oncologists by showcasing the stunning progress in cancer treatment, blending research with heartfelt encouragement.

Dr. Charles Ryan, a leading GU oncologist at Memorial Sloan Kettering, discusses the latest in localized prostate cancer. He highlights the declining PSA screening rates and their impact on diagnosis. The conversation touches on key risk factors like age and genetics, and advances in diagnostics, including genomic data. Hormone therapy's role and patient management strategies are also examined. Additionally, he addresses biochemical recurrence post-treatment and the promising results of recent trials like EMBARK, emphasizing the evolving landscape of prostate cancer care.

Discover the latest breakthroughs in treating metastatic colon cancer. The discussions highlight advances in personalized therapies and the significance of molecular testing. Listeners will learn about effective chemotherapy regimens and the potential of targeted therapies to enhance survival outcomes. The insights shared promise to equip patients and caregivers with essential knowledge in a continually evolving field.